Jason Eric Evans Sells 20,400 Shares of Surgery Partners (NASDAQ:SGRY) Stock

Surgery Partners, Inc. (NASDAQ:SGRY) CEO Jason Eric Evans sold 20,400 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $12.47, for a total transaction of $254,388.00. Following the transaction, the chief executive officer directly owned 920,386 shares in the company, valued at approximately $11,477,213.42. This trade represents a 2.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Jason Eric Evans also recently made the following trade(s):

• On Friday, March 6th, Jason Eric Evans sold 11,462 shares of Surgery Partners stock. The shares were sold at an average price of $13.79, for a total value of $158,060.98.

Surgery Partners Stock Up 2.1%

Shares of NASDAQ:SGRY opened at $12.65 on Wednesday. The business’s 50 day moving average is $14.83 and its 200 day moving average is $17.57. The stock has a market cap of $1.64 billion, a P/E ratio of -20.40 and a beta of 1.95. Surgery Partners, Inc. has a 52-week low of $12.25 and a 52-week high of $24.60. The company has a quick ratio of 1.71, a current ratio of 1.87 and a debt-to-equity ratio of 1.15.

Surgery Partners (NASDAQ:SGRY) last issued its earnings results on Monday, March 2nd. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.19). Surgery Partners had a negative net margin of 2.35% and a positive return on equity of 1.28%. The firm had revenue of $885.00 million for the quarter, compared to the consensus estimate of $866.54 million. During the same period last year, the firm earned $0.44 earnings per share. The company’s revenue for the quarter was up 2.4% on a year-over-year basis. Sell-side analysts predict that Surgery Partners, Inc. will post 0.67 EPS for the current year.

Surgery Partners announced that its board has authorized a stock repurchase plan on Thursday, February 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to repurchase up to 9.7% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Trending Headlines about Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Board authorizes $200M share repurchase (up to ~9.7% of shares), which can support the share price and signals management believes shares are undervalued. Buyback Announcement
• Positive Sentiment: Analyst coverage skews bullish — multiple firms (UBS, Jefferies, Cantor Fitzgerald, Benchmark) have buy/overweight views and the consensus price target (~$23.36) is well above the current price, which supports upside expectations. Analyst Notes
• Positive Sentiment: Large institutional investors have been increasing stakes (Janus Henderson, Pentwater, UBS, Vanguard), showing continued institutional confidence/interest in the stock. Institutional Ownership
• Neutral Sentiment: Q4 results: revenue of $885M beat estimates (~$866.5M) and rose 2.4% year-over-year, which is supportive for top-line trend, but the quarter included a sizable EPS miss. Earnings Report
• Negative Sentiment: CEO Jason Eric Evans sold 20,400 shares at ~$12.47 (≈$254K), a ~2.17% reduction in his holding — a high-profile insider sale that can weigh on investor confidence. Form 4 CEO Sale
• Negative Sentiment: CFO David T. Doherty sold 8,867 shares at ~$12.50 (~$110.8K), trimming his stake by ~3.85%, which may raise governance/sentiment questions. Form 4 CFO Sale
• Negative Sentiment: Other insiders (Jennifer Baldock, Marissa Brittenham, Danielle Burkhalter) executed sales in mid‑March (ranging ~3.5k–5.8k shares each), adding to near-term selling pressure. Insider Trades Summary

Analyst Upgrades and Downgrades

A number of research analysts have commented on SGRY shares. Barclays cut their target price on shares of Surgery Partners from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research report on Tuesday, March 3rd. Jefferies Financial Group reiterated a “buy” rating on shares of Surgery Partners in a research note on Wednesday, March 4th. Benchmark reissued a “buy” rating on shares of Surgery Partners in a report on Tuesday, March 3rd. UBS Group reissued a “buy” rating on shares of Surgery Partners in a research note on Wednesday, March 11th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Surgery Partners in a report on Wednesday, March 4th. Eight research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.36.

Institutional Investors Weigh In On Surgery Partners

A number of institutional investors have recently added to or reduced their stakes in the stock. Hsbc Holdings PLC grew its stake in Surgery Partners by 104.2% in the fourth quarter. Hsbc Holdings PLC now owns 1,931,577 shares of the company’s stock valued at $30,151,000 after purchasing an additional 985,748 shares during the last quarter. Alpine Global Management LLC bought a new stake in shares of Surgery Partners in the 4th quarter valued at about $175,000. Empowered Funds LLC boosted its holdings in shares of Surgery Partners by 1,340.9% in the 4th quarter. Empowered Funds LLC now owns 161,419 shares of the company’s stock valued at $2,494,000 after buying an additional 150,216 shares in the last quarter. One68 Global Capital LLC purchased a new position in shares of Surgery Partners in the 4th quarter worth approximately $371,000. Finally, Man Group plc purchased a new position in shares of Surgery Partners in the 4th quarter worth approximately $5,080,000.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.